Your search for oral corticosteroids returned 51 results

Pulmonary complications are under-recognized in systemic juvenile idiopathic arthritis (sJIA), and are often fatal.

Approaches for management of gout are presented in a two-part guideline.

For patients with severe eosinophilic asthma, treatment with mepolizumab, a monoclonal antibody against interleukin 5, is effective at reducing clinically significant exacerbations.

Systemic corticosteroids are not effective for symptom control in patients with acute rhinosinusitis.

Nurse initiation of oral corticosteroids before physician assessment of pediatric patients with asthma improves quality and efficiency of care provided in the pediatric emergency department.

Novartis announced data from its Phase 3 study of ACZ885 (canakinumab) for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA).

AB Science announced the recruitment of the first patient in its Phase 3 study evaluating masitinib for severe persistent asthma.

Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company’s LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis.

The FDA has approved Promacta tablets (eltrombopag, from GlaxoSmithKline) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have been unresponsive to corticosteroids, immunoglobulins or splenectomy.

The FDA has approved Trivaris (triamcinolone acetonide injectable suspension, from Allergan), a synthetic glucocorticoid corticosteroid, for sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.